Hong et al. 47 found that PARP inhibitors promote lipid peroxidation and ferroptosis in ovarian cancer cells by downregulating SLC7A11 in a p53-dependent manner, thereby inhibiting tumor cancer cell growth. Here, SLC7A11 is linked to ovarian carcinoma.